Age, prostate-specific antigen (PSA), clinical T stage, biopsy Gleason Score (GS), race, and diagnosis year were utilized as factors in multivariable competing risk regression models in the majority of studies, which assessed the impact of various therapies on CSM and OM. The gene discussed is KLK3; the disease is ocular melanoma.